Vanguard Portfolio Management
MPLT

Vanguard Portfolio Management’s MapLight Therapeutics MPLT Stock Holding History

Vanguard Portfolio Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.47M Sell
96,761
-15,843
-14% -$456K ﹤0.01% 2550
2026
Q1 		$2.29M Buy
+112,604
New +$2.01M ﹤0.01% 2561

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management's MPLT Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its MapLight Therapeutics (MPLT) stake by 14% in Q2 2026, selling an estimated $456K and leaving 96,761 shares worth $3.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2550.

Vanguard Portfolio Management first reported a position in MPLT in Q1 2026 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Vanguard Portfolio Management held 96,761 shares of MapLight Therapeutics worth $3.47M as of Q2 2026.
  • Vanguard Portfolio Management sold 15,843 MapLight Therapeutics shares in Q2 2026, an estimated $456K.
  • MapLight Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2550 holding.
  • Vanguard Portfolio Management first reported a position in MapLight Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.